Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic atrophy (GA), a major cause of irreversible sight loss that affects ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a proposed ...

Hereditary optic neuropathies are a prominent cause of blindness in both children and adults. The disorders in this group share many overlapping clinical characteristics, including morphological ...

The Division of Autonomic Disorders, in conjunction with NYU Langone’s Dysautonomia Center, leads a comprehensive clinical research program dedicated to multiple system atrophy (MSA). As a world-class ...

FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease ...